The IL-33, IL-8 And TNF-a Levels in Chronic Hepatitis C Virus Patients
The IL-33, IL-8 And TNF-a Levels in Chronic Hepatitis C Virus Patients
DOI:
https://doi.org/10.36320/ajb/v17.i1.18140Keywords:
Hepatitis C, tumor necrosis factor alpha (TNFα)Abstract
Multiple extrahepatic organ failure is linked to the systemic disease known as hepatitis C virus infection, which contributes to its many symptoms. A kind of immune-modulating molecules called interleukins causes a variety of reactions in tissues and cells. Many of the recognized immunological "second messenger" molecules in mammals are included in these cytokines. TNF-a, IL-33, and IL-18 are linked to the onset of chronicity and liver fibrosis brought on by HCV.
The ill group consisted of 75 individuals with hepatitis C, while the case control group consisted of 75 additional, apparently healthy individuals. The Center of Digestive System in Babylon Province is where the samples were taken between 16 October 2024 to 23 November 2024. Serum levels of IL-33, IL-18, and TNF-a were determined using an ELISA (enzyme-linked immunosorbent assay), and RT-PCR was performed to value the HCV load. The statistical analysis was carried out using SPSS software version 26.
TNF-a, IL-33, and IL-18 levels were higher in patients than in the control group (p < 0.001). The cutoff point for the sensitivity and specificity of IL-18 in the diagnosis of HCV was > 307 ng/ml, according to the ROC curve. 95% CI = (0.754 – 0.925), AUC = 0.82, P. value = 0.0001, and sensitivity and specificity were 75.5% and 82.2%, respectively. Hepatitis C virus progression is influenced by elevated levels of IL-18, IL-33, and TNF-a, which shield hepatic tissue from viral invasion of additional cells.
Downloads
References
1.Rahul Chaudhari, Sherouk Fouda, Ashik Sainu, Joseph M Pappachan. (2021). Metabolic complications of hepatitis C virus. World J Gastroenterol; 27(13): 1267-1282.
2.Lauer GM, Walker BD. (2001) Hepatitis C virus infection. N Engl J Med; 345:41–52.
3.Seeff LB. (2002). Natural history of chronic hepatitis C. Hepatology; 36(Suppl. 1):S35–46.
4. Catanese MT, Uryu K, Kopp M, et al. (2013). Ultrastructural analysis of hepatitis C virus particles. Proc Natl Acad Sci U S A.;110:9505-10.
5. Dubuisson J, Cosset FL. (2014). Virology and cell biology of the hepatitis C virus life cycle: an update. J Hepatol.61:S3-S13.
6. Lindenbach BD, Rice CM. (2013). The ins and outs of hepatitis C virus entry and assembly. Nat Rev Microbiol. 11:688-700.
7. Smith DB, Bukh J, Kuiken C, et al. (2014). Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 59:318-27.
8. Sharma SD. (2010). Hepatitis C virus: molecular biology & current therapeutic options. Indian J Med Res; 131: 17-34
9.Fraser CS, Doudna JA. (2007). Structural and mechanistic insights into hepatitis C viral translation initiation. Nat Rev Microbiol; 5: 29-38
10. Fukushi S, Katayama K, Kurihara C, Ishiyama N, Hoshino FB, Ando T, Oya A. (1994). Complete 5’ noncoding region is necessary for the efficient internal initiation of hepatitis C virus RNA. Biochem Biophys Res Commun ; 199: 425-432.
11. Kohji Moriishi , Yoshiharu Matsuura. (2003). Mechanisms of hepatitis C virus infection. Antivir Chem Chemother. 14(6):285-97.
12.P. Małkowska and M. Sawczuk. 2023. Cytokines as Biomarkers for Evaluating Physical Exercise in Trained and Non-Trained Individuals: A Narrative Review,” International Journal of Molecular Sciences, vol. 24, no. 13. pp: 1-7.
13.C. Liu, D. Chu, K. Kalantar-Zadeh, J. George, H. A. Young, and G. Liu, 2021. Cytokines: From Clinical Significance to Quantification. Advanced Science, vol. 8, no. 15. pp: 1-12.
14. A. Ray. (2016). Cytokines and their Role in Health and Disease: A Brief Overview. MOJ Immunol, vol. 4, no. 2. pp: 1-6.
15. Ahmed G Hegazi and Eman H Abdel-Rahman. (2015). Cytokines,” Innovative Immunology, pp. 1–38.
16. Abdolreza Esmaeilzadeh, Nazila Bahmaie, Elham Nouri, Mohammad Javad Hajkazemi, Maryam Zareh Rafie . (2021). Immunobiological Properties and Clinical Applications of Interleukin-38 for Immune-Mediated Disorders: A Systematic Review Study Int J Mol Sci; 22(22):12552.
17. A. H. Sprague and R. A. Khalil. (2009). Inflammatory cytokines in vascular dysfunction and vascular disease,” Biochemical Pharmacology, vol. 78, no. 6. Elsevier Inc., pp. 539–552.
18. M. Akdis et al. (2011). Interleukins, from 1 to 37, and interferon-γ: receptors, functions, and roles in diseases. J Allergy Clin Immunol, vol. 127, no. 3, pp. 701-721.e70.
19. I. Turchin and M. Bourcier. (2022). The Role of Interleukins in the Pathogenesis of Dermatological Immune-Mediated Diseases,” Adv Ther, vol. 39, no. 10, p. 4474.
20. C. A. J. Vosshenrich and J. P. Di Santo. (2002). Interleukin signaling. Curr Biol, vol. 12, no. 22: 1-9.
21. A. A. J. Vaillant and A. Qurie. (2024) “Interleukin,” Available: https://www.ncbi.nlm.nih.gov/books/NBK499840/
22. Stella Amarachi Ihim, Sharafudeen Dahiru Abubakar, Zeineb Zian6, Takanori Sasaki, Mohammad Saffarioun, Shayan Maleknia9 and Gholamreza Azizi. (2022). Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: Biological role in induction, regulation, and treatment. Frontiers in Immunology, pp: 1-18
23. D.A.B Rex &NupurAgarwal1 Yashwanth Subbannayya, &T.S.Keshava Prasad &SnehaM. (2020). A comprehensive pathway map of IL-18-mediated signaling. Journal of Cell Communication and Signaling, vol. 14, pp:257–266.
24. Gilles Kaplansk. (2018). Interleukin-18: Biological properties and role in disease pathogenesis mmunol Rev. 281(1):138-153.
25. Charles A Dinarello , Daniela Novick , Soohyun Kim , Gilles Kaplanski .(2013). Interleukin-18 and IL-18 Binding Protein. Front Immunol.8;4:289.
26. Markowitz, G. J., Yang, P., Fu, J., Michelotti, G. A., Chen, R., Sui, J.Wang, X. F. (2016). Inflammation-dependent IL18 signaling restricts hepatocellular carcinoma growth by enhancing the accumulation and activity of tumor- infiltrating lymphocytes. Cancer Research, 76(8), 2394–2405.
27. X.-M. Yi, H. Lian, and S. Li. (2022). Signaling and functions of interleukin-33 in immune regulation and diseases. Cell Insight, vol. 1, no. 4, p. 100042.
28. C. Cayrol and J. P. Girard. (2018). Interleukin-33 (IL-33): A nuclear cytokine from the IL-1 family,” Immunol Rev, vol. 281, no. 1, pp. 154–168. doi: 10.1111/IMR.12619.
28. C. Afferni et al.,(2018). The pleiotropic immunomodulatory functions of IL-33 and its implications in tumor immunity. Frontiers in Immunology, vol. 9, pp: 1-17.
29. Wael Hegazy, Mohamed Henawy. (2015). Hepatitis C virus pathogenesis: Serum IL-33 level indicates liver damage. African Journal of Microbiology Research 9(20):1386-1393
30. Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T. (2010). Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford); 49(7):1215–28.
31.Knobler H, Schattner A. (2005). TNF-{alpha}, chronic hepatitis C and diabetes: a novel triad. QJM.;98(1):1–6.
32.Itoh Y, Okanoue T, Ohnishi N, Sakamoto M, Nishioji K, Nakagawa Y, et al. (1999). Serum levels of soluble tumor necrosis factor receptors and effects of interferon therapy in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 94(5):1332–40.
33. Kallinowski B, Haseroth K, Marinos G, Hanck C, Stremmel W, Theilmann L, et al. (1998). Induction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection. Clinical and experimental immunology. 111(2):269–77..
34. Beutler B, Greenwald D, Hulmes JD, Chang M, Pan YC, Mathison J, et al. (1985). Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature. 316(6028):552–4.
35 Ashfaq UA, Javed T, Rehman S, Nawaz Z, Riazuddin S. (2011). An overview of HCV molecular biology, replication and immune responses. Virol J.;8:161 , pp:1-10.
36. Schmidt, SD; Mazzella, MJ; Nixon, RA; Mathews, PM (2012). Aβ Measurement by Enzyme-Linked Immunosorbent Assay. Amyloid Proteins. Methods in Molecular Biology. Vol. 849. pp. 507–27.
37. Hongxin Fan and Ryan S. (2010). Robetorye Real-Time Quantitative Reverse Transcriptase Polymerase Chain Reaction. Protocol, vol. 360, pp: 199- 213.
38. barianne. t-test & ANOVA (Analysis of Variance) - Discovery in the Post-Genomic Age. Bioinformatics, Biostatistics. 2018.
19.Octavie Rostan, Muhammad Imran Arshad, Claire Piquet Pellorce, Florence Robert-Gangneux, Jean-Pierre Gangneux, Michel Samson. (2015). Crucial and Diverse Role of the Interleukin-33/ST2 Axis in Infectious Diseases. Infection and Immunit, Volume 83 Number 5: 1738 – 1748
40. Wael Abdel Halim Hegazy and Mohamed Abdelrahman Henawy. (2015). Hepatitis C virus pathogenesis: Serum IL-33 level indicates liver damage . African Journal of Microbiology Research, Vol. 9(20), pp. 1386-1393.
41. Ahmed A. Salama, Atef A. Alim , Esraa E. Elmahdy, Esraa E. Elmahdy. (2017). Role of interleukin-33 in patients with chronic hepatitis C in Role of interleukin-33 in patients with chronic hepatitis C in Menoufia University Hospitals, Egypt Menoufia University Hospitals, Egypt. Monofia university journal, vol. 30, pp: 249 – 254.
42. Sebastian Wawrocki, Magdalena Druszczynska, Magdalena Kowalewicz-Kulbat and Wieslawa Rudnicka. (2016). Interleukin 18 (IL-18) as a target for immune intervention. Acta Biochemica Polonica, Vol. 63, No 1; pp:59–63.
43. Morvarid Asadipour, Pooria Fazeli1, Mahshid Zohouri, Peyman Bemani, Mohsen Mohebbiniya, Soolmaz Khansalar, Mohammad Reza Fattahi and Kurosh kalantar. (20200. IL-18 in Blood Serum of Hepatitis C Patients Might be of Predictive Value for Individual Outcomes..net Infectious Disorders - Drug Targets, 20 , pp: 1-5.
44. Michael A. Chattergoon, Jordana S. Levine, Rachel Latanich, William O. Osburn, David L. Thomas and Andrea L. Cox. (2011). High Plasma Interleukin-18 Levels Mark the Acute Phase of Hepatitis C Virus Infection. The Journal of Infectious Diseases, Vol. 204, No. 11, pp. 1730-1740.
45. Arpita Sharma, Anuradha Chakraborti, Ashim Das, Radha Krishan Dhiman and Yogesh Chawla. (2009). Elevation of interleukin-18 in chronic hepatitis C: implications for hepatitis C virus pathogenesis. Immunology, 128,pp: e514–e522.
46. Amr Elrabata, Shahera Eletrebya, Ahmed M. Ali Zaida, Mohammed H. Eldeen Zaghloulb. (2019). Tumor necrosis factor-alpha and alpha-fetoprotein as biomarkers for diagnosis and follow-up of hepatocellular carcinoma before and after interventional therapy. The Egyptian Journal of Internal Medicine , 31, pp:840–848.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Ghaith Kareem Abdul Hasan Alhijami, Seçil Akilli ŞIMŞEK1
This work is licensed under a Creative Commons Attribution 4.0 International License.
which allows users to copy, create extracts, abstracts, and new works from the Article, alter and revise the Article, and make commercial use of the Article (including reuse and/or resale of the Article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work.
